The trial is scheduled to last for three years.ĭenverSpine is enrolling study participants suffering from moderate low-back pain for a minimum of six months and whose condition has not responded to other, conventional treatments. About 10 – 20 participants will be enrolled at the Denver site and the rest at 11 other medical centers throughout the United States. Researchers will enroll approximately 100 study participants. “The study is the first of its kind in the United States and we are very excited by the potential of these adult stem cells to provide a novel therapeutic approach,” said Dr. Both doctors agree on the critical need for a minimally invasive solution to a common, debilitating condition. is the lead researcher providing spinal injections for the study, and Gary Ghiselli, M.D. However, these surgeries often are not entirely effective.
Most patients with low-back pain respond to physical therapy and medications, but in advanced cases, artificial disc replacement or spinal fusion - removal of the degenerated discs and the fusion of the bones of the spine - is necessary. Degenerative disc disease is the most common cause of low-back pain, which develops with the gradual loss of a material called proteoglycan, which cushions the bones of the spine and enables normal motion. The minimally invasive procedure may offer an alternative to back surgery for eligible patients with chronic pain from degenerative discs.Īn estimated 30 million people in the United States suffer from back pain. The study will test the use of Mesenchymal Precursor Cells (MPCs) – adult stem cells derived from bone marrow that will be directly injected into the lumbar disc. Denver Spine Physicians Begin Enrollment in United States Stem Cell Therapy StudyĭenverSpine today announced that it has enrolled its first patient in a nationwide FDA- cleared adult stem cell study testing novel treatment for chronic low back pain.
0 kommentar(er)
